|
Mar 14
|
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
|
|
Mar 12
|
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
|
|
Feb 20
|
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
|
|
Feb 19
|
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
|
|
Jan 3
|
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 25
|
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
|
|
Jul 31
|
Palisade Bio Participates in Virtual Investor “What this Means” Segment
|
|
Jul 29
|
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
|
|
Jun 24
|
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
|
|
Jun 21
|
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
|
|
May 7
|
Palisade Bio Appoints Margery Fischbein to its Board of Directors
|
|
May 7
|
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
|
|
Apr 3
|
Palisade Bio Announces 1-for-15 Reverse Stock Split
|
|
Jan 9
|
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
|
|
Dec 28
|
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
|